What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for ELTP (
Elite Pharmaceuticals Inc
) from 2009 to Apr 24 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Elite Pharmaceuticals stock (ELTP) PE ratio as of Apr 24 2025 is 0.
More Details
Elite Pharmaceuticals Inc (ELTP) PE Ratio (TTM) Chart
Elite Pharmaceuticals Inc (ELTP) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 1212
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Elite Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2025-04-24 | At Loss | 2025-02-19 | At Loss |
| 2025-04-23 | At Loss | 2025-02-18 | At Loss |
| 2025-04-22 | At Loss | 2025-02-14 | At Loss |
| 2025-04-21 | At Loss | 2025-02-13 | At Loss |
| 2025-04-17 | At Loss | 2025-02-12 | At Loss |
| 2025-04-16 | At Loss | 2025-02-11 | At Loss |
| 2025-04-15 | At Loss | 2025-02-10 | At Loss |
| 2025-04-14 | At Loss | 2025-02-07 | At Loss |
| 2025-04-11 | At Loss | 2025-02-06 | At Loss |
| 2025-04-10 | At Loss | 2025-02-05 | At Loss |
| 2025-04-09 | At Loss | 2025-02-04 | At Loss |
| 2025-04-08 | At Loss | 2025-02-03 | At Loss |
| 2025-04-07 | At Loss | 2025-01-31 | At Loss |
| 2025-04-04 | At Loss | 2025-01-30 | At Loss |
| 2025-04-03 | At Loss | 2025-01-29 | At Loss |
| 2025-04-02 | At Loss | 2025-01-28 | At Loss |
| 2025-04-01 | At Loss | 2025-01-27 | At Loss |
| 2025-03-31 | At Loss | 2025-01-24 | At Loss |
| 2025-03-28 | At Loss | 2025-01-23 | At Loss |
| 2025-03-27 | At Loss | 2025-01-22 | At Loss |
| 2025-03-26 | At Loss | 2025-01-21 | At Loss |
| 2025-03-25 | At Loss | 2025-01-17 | At Loss |
| 2025-03-24 | At Loss | 2025-01-16 | At Loss |
| 2025-03-21 | At Loss | 2025-01-15 | At Loss |
| 2025-03-20 | At Loss | 2025-01-14 | At Loss |
| 2025-03-19 | At Loss | 2025-01-13 | At Loss |
| 2025-03-18 | At Loss | 2025-01-10 | At Loss |
| 2025-03-17 | At Loss | 2025-01-08 | At Loss |
| 2025-03-14 | At Loss | 2025-01-07 | At Loss |
| 2025-03-13 | At Loss | 2025-01-06 | At Loss |
| 2025-03-12 | At Loss | 2025-01-03 | At Loss |
| 2025-03-11 | At Loss | 2025-01-02 | At Loss |
| 2025-03-10 | At Loss | 2024-12-31 | At Loss |
| 2025-03-07 | At Loss | 2024-12-30 | At Loss |
| 2025-03-06 | At Loss | 2024-12-27 | At Loss |
| 2025-03-05 | At Loss | 2024-12-26 | At Loss |
| 2025-03-04 | At Loss | 2024-12-24 | At Loss |
| 2025-03-03 | At Loss | 2024-12-23 | At Loss |
| 2025-02-28 | At Loss | 2024-12-20 | At Loss |
| 2025-02-27 | At Loss | 2024-12-19 | At Loss |
| 2025-02-26 | At Loss | 2024-12-18 | At Loss |
| 2025-02-25 | At Loss | 2024-12-17 | At Loss |
| 2025-02-24 | At Loss | 2024-12-16 | At Loss |
| 2025-02-21 | At Loss | 2024-12-13 | At Loss |
| 2025-02-20 | At Loss | 2024-12-12 | At Loss |
Elite Pharmaceuticals Inc (ELTP) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Elite Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US28659T2006
Description
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers